had a higher impact from the decline in domestic purchasing power leading to lower prepaid usage despite an increase in tourism-related income. Competition remained intense with the market continued
were back on track with 44.5% growth YoY and 3.4% growth QoQ. - In Q1’19, the Company maintained its leadership position with total market share of 31.1% in Brain and Body Boost (“BBB”) products which
Company recorded a share of loss from investment in joint ventures & associates of THB 92mn. The recognition of share of loss was mainly from the severely impact from COVID-19 pandemic in Indonesia market
Ratio (Times) N/A N/A N/A Cash Basis (Times) 1.48 1.48 1.11 Dividend paid (%) * - 99.90 99.90 Per-Share Data and Growth Rate of All Types of Business 2016 2015 2014 Per-share Data Book Value per share
-200% 0 -1,789 -100% EPS (Baht/share) -0.02 -1.81 -99% 0.02 -200% 0.00 -1.75 -100% Note : (1) Adjusted EBITDA refers to EBITDA excluding impact of Stock Gain/(Loss) and NRV (2) Extra items were expenses
overall selling price decrease, especially for Caustic Soda due to the fall of its market price trend, plus impact from appreciation of Thai Baht against US Dollar. However, those negative impacts were
Baht/USD 35.18 at 30/06/16 (34.45 at 31/03/17) or the respective rate applicable to each offshore subsidiary's base currency. Payout Analysis In Q217 THB 805m final dividend of THB 1.00 per share was
sales from lower EDC purchase plus greater ECH sales from the additional volume to China, Taiwan and Indian accounts. The share of domestic and export sales have no significant change comparing to the
currency. Payout Analysis In Q219 THB 805m final dividend of THB 1.00 per share was paid during the quarter from the profits of 2018. In Q218 THB 805m final dividend of THB 1.00 per share was paid during
to each offshore subsidiary's base currency. Payout Analysis In Q218 THB 805m final dividend of THB 1.00 per share was paid during the quarter from the profits of 2017. In Q217 THB 805m final dividend